XTX Topco Ltd Boosts Position in Vaxart, Inc. (NASDAQ:VXRT)

XTX Topco Ltd grew its holdings in shares of Vaxart, Inc. (NASDAQ:VXRT) by 869.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 136,466 shares of the biotechnology company’s stock after buying an additional 122,387 shares during the quarter. XTX Topco Ltd owned 0.08% of Vaxart worth $116,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in VXRT. Monaco Asset Management SAM purchased a new stake in Vaxart during the 2nd quarter worth $402,000. Millennium Management LLC lifted its stake in shares of Vaxart by 110.8% during the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after purchasing an additional 2,095,274 shares in the last quarter. Finally, Mesirow Financial Investment Management Inc. boosted its position in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Stock Performance

VXRT stock opened at $0.62 on Friday. The stock has a 50-day simple moving average of $0.68 and a 200-day simple moving average of $0.73. The firm has a market cap of $140.95 million, a P/E ratio of -1.51 and a beta of 0.62. Vaxart, Inc. has a 1 year low of $0.52 and a 1 year high of $1.54.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.